Dataset Information

Data on differentially expressed microRNAs in the liver between nonalcoholic fatty liver disease and normal Wistar rat using Solexa sequencing.

ABSTRACT: The dataset includes data from the Solexa sequencing reported in our paper: "Identification and differential expression of microRNAs associated with fat deposition in the liver of Wistar rats with nonalcoholic fatty liver disease" [1]. The data collected include small RNAs and microRNAs in liver tissue from high glucose-induced NAFLD Wistar rats, using normal Wistar rats as their negative controls. 6 small RNA libraries were constructed and the expression profiles were compared between the two groups. Here we describe in detail how the data, deposited in the Gene Expression Omnibus (GEO) with the accession number GEO: GSE68411, was generated including the basic analysis.

SUBMITTER: Zhang D

PROVIDER: S-EPMC4906032 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Data on differentially expressed microRNAs in the liver between nonalcoholic fatty liver disease and normal Wistar rat using Solexa sequencing.

Zhang Deqing D Wang Yuqian Y Ji Zhibin Z Wang Zhonghua Z

Data in brief 20160524

The dataset includes data from the Solexa sequencing reported in our paper: "Identification and differential expression of microRNAs associated with fat deposition in the liver of Wistar rats with nonalcoholic fatty liver disease" [1]. The data collected include small RNAs and microRNAs in liver tissue from high glucose-induced NAFLD Wistar rats, using normal Wistar rats as their negative controls. 6 small RNA libraries were constructed and the expression profiles were compared between the two g ...[more]

PMID: 27331102

Similar Datasets

Project description:Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent forms of chronic liver disease in the United States and worldwide. Nonalcoholic steatohepatitis (NASH), the most advanced form of NAFLD, is characterized by hepatic steatosis associated with inflammation and hepatocyte death. No treatments are currently available for NASH other than lifestyle changes, and the disease lacks specific biomarkers. The signaling lymphocytic activation molecule family 1 (SLAMF1) protein is a self-ligand receptor that plays a role in orchestrating an immune response to some pathogens and cancers. We found that livers from humans and mice with NASH showed a more prominent immunohistochemistry staining for SLAMF1 than non-NASH controls. Furthermore, SLAMF1 levels are significantly increased in NASH plasma samples from mice and humans compared with their respective controls. In mice, the levels of SLAMF1 correlated significantly with the severity of the NASH phenotype. To test whether SLAMF 1 is expressed by hepatocytes, HepG2 cells and primary murine hepatocytes were treated with palmitic acid (PA) to induce a state of lipotoxicity mimicking NASH. We found that PA treatments of HepG2 cells and primary hepatocytes lead to significant increases in SLAMF1 levels. The downregulation of SLAMF1 in HepG2 cells improved the cell viability and reduced cytotoxicity. The in vivo data using mouse and human NASH samples suggests a potential role for this protein as a noninvasive biomarker for NASH. The in vitro data suggest a role for SLAMF1 as a potential therapeutic target to prevent hepatocyte death in response to lipotoxicity.NEW & NOTEWORTHY This study identified for the first time SLAMF1 as a mediator of hepatocyte death in nonalcoholic fatty liver disease (NASH) and as a marker of NASH in humans. There are no pharmacological treatments available for NASH, and diagnostic tools are limited to invasive liver biopsies. Therefore, since SLAMF1 levels correlate with disease progression and SLAMF1 mediates cytotoxic effects, this protein can be used as a therapeutic target and a clinical biomarker of NASH.

Dataset Information

Data on differentially expressed microRNAs in the liver between nonalcoholic fatty liver disease and normal Wistar rat using Solexa sequencing.

Publications

Data on differentially expressed microRNAs in the liver between nonalcoholic fatty liver disease and normal Wistar rat using Solexa sequencing.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets